Skip to main content
. Author manuscript; available in PMC: 2018 Jan 13.
Published in final edited form as: Cancer. 2016 Aug 17;122(21):3344–3353. doi: 10.1002/cncr.30258

Table 3. Response to treatment with PD-1 and PD-L1 antibodies.

Best overall response1, 2 No. (%)
(N=56)
Complete response 0
Partial response 2 (3.6)
Stable disease ≥ 6 months 5 (8.9)
Progressive disease 48 (85.7)
1

The best overall response was assessed by the investigator with the use of the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.

2

Response not included for a patient who was lost to follow-up with stable disease at 5 months.